Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 9/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540906 | 1.00 | CHRNB4 (0.44) | CHRNB4CHRNA3TGFBR1ACVR1KCNH2 | |
| SCHEMBL3704744 | 0.80 | MAPT (0.41) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3529321 | 0.76 | ADRA2C (0.51) | PTPN11 | |
| SCHEMBL2448998 | 0.76 | ADRA2C (0.51) | PTPN11 | |
| SCHEMBL3538907 | 0.75 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL3538904 | 0.75 | CHRNB4 (0.49) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL23515037 | 0.73 | GAA (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL16069835 | 0.73 | MAPT (0.47) | TGFBR1ACVR1KCNH2PTPN11 | |
| SCHEMBL3528425 | 0.73 | MAPT (0.47) | TGFBR1ACVR1KCNH2PTPN11 | |
| SCHEMBL15132388 | 0.73 | CHRNB4 (0.41) | CHRNB4CHRNA3TGFBR1ACVR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713978-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-05-11 | — | — | US | disclosed |
| US-7713978-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-05-11 | — | — | US | disclosed |
| US-7713978-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-05-11 | — | — | US | disclosed |
| EP-2013178-A1 | PIPERAZINE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUE (GHS) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238737-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238737-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238737-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| WO-2007113202-A1 | PIPERAZINE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUE (GHS) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113202-A1 | PIPERAZINE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUE (GHS) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238737-A1 | NOVEL COMPOUNDS | FABP2, VIP, SLC10A2 | CHRNB4 2397/4885CHRNA3 2876/4885TGFBR1 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.